Cian Healthcare Secures BSE Listing Post-Insolvency, Promoter Stake Surges to 95%

Cian Healthcare Limited has received approval from the BSE to list 2.375 crore equity shares, valued at ₹237.50 crore. These shares were issued to the company's promoters on a preferential basis as part of its resolution plan.

This approval is a significant step in the company's revival after its Corporate Insolvency Resolution Process (CIRP). The company is now completing the necessary steps to begin trading on the exchange.

Why This Matters

The listing signifies the implementation of the resolution plan approved by the National Company Law Tribunal (NCLT). It allows Cian Healthcare to resume normal trading activities, aiming to rebuild investor confidence after a period of insolvency.

Company's Journey Through Insolvency

Cian Healthcare, a pharmaceutical and nutraceutical manufacturer, entered the Corporate Insolvency Resolution Process (CIRP) in June 2024 due to a claim from an operational creditor. The NCLT Mumbai Bench approved the resolution plan submitted by Mr. Pradeep Kumar Jain, the successful applicant, on December 18, 2025. This plan included a settlement amount of ₹37.30 crore.

A key part of the plan involved significant share capital restructuring. Existing promoter shares were cancelled, and public shareholding was reduced. Fresh equity of 2.375 crore shares was then issued to prospective promoters for ₹23.75 crore. This expanded the company's equity share capital from ₹1.25 crore to ₹25.00 crore.

This restructuring led to the promoter group consolidating its holding to a commanding 95% of the company's equity share capital.

What Changes Now

• Trading Resumption: Shares are cleared for listing, enabling trading activities once exchange formalities are completed.
• Promoter Control: The promoter group now holds a substantial majority stake (95%), centralizing control.
• Revival Phase: This marks a formal exit from insolvency, with the company expected to focus on operational recovery.
• Shareholder Dilution: Existing public shareholders likely experienced significant dilution or extinguishment of their holdings during the resolution process.

Risks to Watch

• SEBI Compliance: Failure to apply for trading approval within seven working days of the BSE listing approval could result in SEBI-imposed fines.
• Governance Scrutiny: The high promoter stake (95%) may raise governance concerns and reduce the public float, requiring investor monitoring.
• Operational Performance: The company's ability to execute its revival strategy and achieve sustainable profitability post-CIRP remains a key challenge.

What to Track Next

• Trading Formalities: Completion of procedural requirements for trading on the BSE.
• NSE Listing: Confirmation of whether the company seeks listing approval on the National Stock Exchange of India Ltd.
• Regulatory Filings: Submission of confirmation letters from NSDL/CDSL regarding share crediting and lock-in periods.
• Financial Performance: Monitoring revenue, profitability, and debt levels post-CIRP.
• Governance Watch: Observing how concentrated promoter control affects future decisions and minority shareholder interests.